A M Minnis1, N S Padian. 1. Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, 74 New Montgomery, Suite 600, San Francisco, CA 94105, USA. aminnis@psg.ucsf.edu
Abstract
OBJECTIVES: To evaluate evidence for the effectiveness of female controlled physical and chemical barrier methods in preventing STI/HIV transmission, to examine recent reviews on microbicide development, and to highlight promising research directions. To discuss challenges in conducting effectiveness research and in translating results to public health intervention. METHODS: Systematic review of articles that examined the disease prevention effectiveness of at least one female controlled barrier method. Review of conference abstracts that presented clinical and preclinical microbicide data. RESULTS: Randomised controlled trials provide evidence that female condoms confer as much protection from STIs as male condoms. Observational studies suggest that the diaphragm protects against STI pathogens. Several microbicide effectiveness studies are under way and new directions, such as adaptation of therapeutic agents as preventive products, are being examined. Substantial attention is now given to product formulation and novel delivery strategies. Combining microbicide products with different mechanisms of action as well as combining chemical and physical barriers will be necessary to maximise prevention effectiveness. CONCLUSIONS: Increased investment in the development and identification of female controlled barrier methods offers promise that additional products will be available in the years ahead. Generalizing trial results to a community setting, promoting products that may be less effective than male condoms, and bringing an effective product to scale introduce public health challenges that warrant attention. The need for female controlled barrier methods that provide women with the opportunity to take an active role in reducing their STI/HIV risk are urgently needed and constitute an essential tool to prevent continued spread of these infections.
OBJECTIVES: To evaluate evidence for the effectiveness of female controlled physical and chemical barrier methods in preventing STI/HIV transmission, to examine recent reviews on microbicide development, and to highlight promising research directions. To discuss challenges in conducting effectiveness research and in translating results to public health intervention. METHODS: Systematic review of articles that examined the disease prevention effectiveness of at least one female controlled barrier method. Review of conference abstracts that presented clinical and preclinical microbicide data. RESULTS: Randomised controlled trials provide evidence that female condoms confer as much protection from STIs as male condoms. Observational studies suggest that the diaphragm protects against STI pathogens. Several microbicide effectiveness studies are under way and new directions, such as adaptation of therapeutic agents as preventive products, are being examined. Substantial attention is now given to product formulation and novel delivery strategies. Combining microbicide products with different mechanisms of action as well as combining chemical and physical barriers will be necessary to maximise prevention effectiveness. CONCLUSIONS: Increased investment in the development and identification of female controlled barrier methods offers promise that additional products will be available in the years ahead. Generalizing trial results to a community setting, promoting products that may be less effective than male condoms, and bringing an effective product to scale introduce public health challenges that warrant attention. The need for female controlled barrier methods that provide women with the opportunity to take an active role in reducing their STI/HIV risk are urgently needed and constitute an essential tool to prevent continued spread of these infections.
Authors: Jeffrey N Martin; Michelle E Roland; Torsten B Neilands; Melissa R Krone; Joshua D Bamberger; Robert P Kohn; Margaret A Chesney; Karena Franses; James O Kahn; Thomas J Coates; Mitchell H Katz Journal: AIDS Date: 2004-03-26 Impact factor: 4.177
Authors: Che-Chung Tsai; Peter Emau; Yonghou Jiang; Baoping Tian; William R Morton; Kirk R Gustafson; Michael R Boyd Journal: AIDS Res Hum Retroviruses Date: 2003-07 Impact factor: 2.205
Authors: S C Thomsen; W Ombidi; C Toroitich-Ruto; E L Wong; H O Tucker; R Homan; N Kingola; S Luchters Journal: Sex Transm Infect Date: 2006-07-19 Impact factor: 3.519
Authors: Miriam Hartmann; Michele Lanham; Thesla Palanee-Phillips; Florence Mathebula; Elizabeth E Tolley; Dean Peacock; Laura Pascoe; Seth Zissette; Sarah T Roberts; Danielle Wagner; Ellen Wilson; Asha Ayub; Rose Wilcher; Elizabeth T Montgomery Journal: AIDS Educ Prev Date: 2019-10
Authors: Manuel V Villaran; Angela Bayer; Kelika A Konda; Carlos Mendoza; Hilda Quijandria; Julia S Ampuero; Moises Apolaya; Oswaldo Palacios; Andres G Lescano; Antonio M Vega; David L Blazes; Tadeusz Kochel; Silvia M Montano Journal: Am J Mens Health Date: 2012-03-07
Authors: Frieda M Behets; Abigail Norris Turner; Kathleen Van Damme; Ny Lovaniaina Rabenja; Noro Ravelomanana; Teresa A Swezey; April J Bell; Daniel R Newman; D'Nyce L Williams; Denise J Jamieson Journal: Sex Transm Dis Date: 2008-09 Impact factor: 2.830
Authors: Elizabeth A Bukusi; Maria F Gallo; Anjali Sharma; Betty Njoroge; Denise J Jamieson; Rosemary Nguti; April J Bell; David A Eschenbach Journal: Infect Dis Obstet Gynecol Date: 2010-03-07